{"id":"piperacillin-tazobactam-combination-product","safety":{"commonSideEffects":[{"rate":"5-15","effect":"Diarrhea"},{"rate":"3-10","effect":"Nausea"},{"rate":"1-5","effect":"Vomiting"},{"rate":"2-8","effect":"Rash"},{"rate":"2-5","effect":"Phlebitis at injection site"},{"rate":"1-3","effect":"Headache"},{"rate":null,"effect":"Clostridium difficile-associated diarrhea"}]},"_chembl":{"chemblId":"CHEMBL1200820","moleculeType":"Small molecule","molecularWeight":"539.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Piperacillin is an extended-spectrum penicillin that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking, leading to cell lysis and death. Tazobactam is a beta-lactamase inhibitor that irreversibly binds to and inactivates bacterial beta-lactamases, preventing enzymatic destruction of piperacillin and restoring its activity against beta-lactamase-producing organisms.","oneSentence":"Piperacillin-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:00:22.724Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections"},{"name":"Nosocomial pneumonia"},{"name":"Febrile neutropenia in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT04948463","phase":"PHASE4","title":"Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2021-11-15","conditions":"Febrile Neutropenia","enrollment":55},{"nctId":"NCT07481539","phase":"PHASE2","title":"Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment","status":"RECRUITING","sponsor":"Azienda Sanitaria Universitaria Friuli Centrale","startDate":"2026-03-24","conditions":"Bacteria Infection, Piperacillin, Tazobactam Drug Combination","enrollment":240},{"nctId":"NCT06712641","phase":"PHASE4","title":"Aminoglycosides in Early Sepsis","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Akershus","startDate":"2026-04","conditions":"Sepsis","enrollment":1900},{"nctId":"NCT03078010","phase":"PHASE2","title":"Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-02-10","conditions":"Intestinal Microbiome, Febrile Neutropenia","enrollment":347},{"nctId":"NCT04514653","phase":"PHASE2","title":"RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2020-08-25","conditions":"Neovascular Age-Related Macular Degeneration (nAMD)","enrollment":146},{"nctId":"NCT06954129","phase":"PHASE4","title":"A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients","status":"RECRUITING","sponsor":"University of Pennsylvania","startDate":"2026-01-28","conditions":"Acute Kidney Injury","enrollment":750},{"nctId":"NCT06123169","phase":"PHASE3","title":"Postoperative Anti-infective Strategy Following Pancreaticoduodenectomy in Patients With Preoperative Biliary Stent","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2026-04","conditions":"Pancreaticoduodenectomy, Antibiotherapy","enrollment":326},{"nctId":"NCT06426836","phase":"NA","title":"Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)","status":"RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2016-08-19","conditions":"Pharmacokinetics, Amoxicillin-clavulanate, Piperacillin-tazobactam","enrollment":300},{"nctId":"NCT02473263","phase":"PHASE3","title":"Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-05-09","conditions":"Severe Septic Syndrome (Severe Sepsis and Septic Shock) Diagnosed and Treated by Mobile Intensive Care Unit","enrollment":398},{"nctId":"NCT03269994","phase":"PHASE3","title":"Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-21","conditions":"Pancreatic Cancer, Pancreas Cancer, Pancreatic Diseases","enrollment":967},{"nctId":"NCT07096310","phase":"PHASE1, PHASE2","title":"Comparison Between Carbapenems and Noncarbapenem Beta-lactam Antibiotics in Septic Burn Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2024-01-01","conditions":"Sepsis","enrollment":400},{"nctId":"NCT05977868","phase":"PHASE4","title":"Comparing Oral Versus Parenteral Antimicrobial Therapy","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2023-08-04","conditions":"Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection","enrollment":94},{"nctId":"NCT03671967","phase":"PHASE4","title":"PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)","status":"RECRUITING","sponsor":"Rambam Health Care Campus","startDate":"2019-05-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":1084},{"nctId":"NCT05355350","phase":"PHASE4","title":"PipEracillin/Tazobactam Versus mERoPENem for Treatment of AmpC Producing Blood Stream Infections","status":"WITHDRAWN","sponsor":"Rambam Health Care Campus","startDate":"2022-07-01","conditions":"Beta Lactam Resistant Bacterial Infection, Enterobacteriaceae Infections, Bacteremia","enrollment":""},{"nctId":"NCT06184659","phase":"PHASE4","title":"Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis","status":"RECRUITING","sponsor":"Scandinavian Critical Care Trials Group","startDate":"2025-06-26","conditions":"Sepsis, Septic Shock","enrollment":5800},{"nctId":"NCT06977347","phase":"NA","title":"Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea","status":"NOT_YET_RECRUITING","sponsor":"CHOSEOK YOON","startDate":"2025-06-15","conditions":"Severe Community-acquired Pneumonia (sCAP)","enrollment":100},{"nctId":"NCT06342115","phase":"PHASE4","title":"Ceftolozane/Tazobactam Versus Meropenem for Febrile Neutropenia on Patients Colonized With or at Risk for Infection With Extended Spectrum Beta Lactamase - Producing Pathogens","status":"RECRUITING","sponsor":"Beneficência Portuguesa de São Paulo","startDate":"2025-03-26","conditions":"Febrile Neutropenia","enrollment":176},{"nctId":"NCT06929702","phase":"PHASE4","title":"Precision Dosing of Beta-lactam Antibiotics in Critically Ill Children","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Ghent","startDate":"2025-04-22","conditions":"Amoxicillin-clavulanate, Piperacillin-tazobactam, Meropenem","enrollment":58},{"nctId":"NCT02820987","phase":"PHASE3","title":"PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2016-09-27","conditions":"Septic Shock","enrollment":119},{"nctId":"NCT03891433","phase":"PHASE4","title":"Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae","status":"SUSPENDED","sponsor":"Universidad del Norte","startDate":"2019-04-01","conditions":"Urinary Tract Infections, Enterobacteriaceae Infections, Infection Due to ESBL Bacteria","enrollment":198},{"nctId":"NCT04983901","phase":"PHASE2","title":"PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-14","conditions":"Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm","enrollment":100},{"nctId":"NCT04803422","phase":"NA","title":"Per Oral Versus Intravenous Postoperative Antibiotics After Surgery for Complicated Appendicitis.","status":"COMPLETED","sponsor":"Zealand University Hospital","startDate":"2021-04-01","conditions":"Complicated Appendicitis","enrollment":3193},{"nctId":"NCT05753735","phase":"PHASE2","title":"eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF","status":"TERMINATED","sponsor":"Case Comprehensive Cancer Center","startDate":"2024-01-18","conditions":"Pancreatic Fistula","enrollment":3},{"nctId":"NCT04276480","phase":"NA","title":"Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2022-02-16","conditions":"Enterobacteriaceae Infections","enrollment":9},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT06422533","phase":"NA","title":"Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients","status":"RECRUITING","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2023-11-07","conditions":"Hematologic Neoplasms, Neutropenia","enrollment":226},{"nctId":"NCT03289351","phase":"PHASE4","title":"Two Different Antibiotics Versus One Antibiotic for Pediatric Perforated Appendicitis","status":"COMPLETED","sponsor":"Phoenix Children's Hospital","startDate":"2017-05-22","conditions":"Perforated Appendicitis, Postoperative Infection","enrollment":162},{"nctId":"NCT04724044","phase":"PHASE3","title":"Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2021-01-25","conditions":"Community-acquired Pneumonia, Sepsis, Inflammatory Response","enrollment":278},{"nctId":"NCT03159754","phase":"PHASE4","title":"Optimal Care of Complicated Appendicitis","status":"COMPLETED","sponsor":"University of Michigan","startDate":"2017-06-29","conditions":"Appendicitis, Perforated Appendicitis, Ruptured Appendicitis","enrollment":40},{"nctId":"NCT04033029","phase":"","title":"Antibiotic Plasma Concentrations During Continuous Renal Replacement Therapy With a High Adsorption Membrane (oXiris®)","status":"COMPLETED","sponsor":"Hospital Universitari de Bellvitge","startDate":"2021-01-01","conditions":"Hemodiafiltration, Sepsis, Acute Kidney Injury","enrollment":20},{"nctId":"NCT01431326","phase":"","title":"Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care","status":"COMPLETED","sponsor":"Daniel Benjamin","startDate":"2011-11","conditions":"Adenovirus, Anesthesia, Anxiety","enrollment":3520},{"nctId":"NCT05981079","phase":"PHASE4","title":"Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2023-07-31","conditions":"Late-Onset Neonatal Sepsis","enrollment":332},{"nctId":"NCT05943223","phase":"PHASE2","title":"Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)","status":"UNKNOWN","sponsor":"McMaster Children's Hospital","startDate":"2024-01","conditions":"Appendicitis Perforated","enrollment":16},{"nctId":"NCT03262142","phase":"PHASE4","title":"Targeted AntiBiotics for Chronic Pulmonary Diseases","status":"TERMINATED","sponsor":"Chronic Obstructive Pulmonary Disease Trial Network, Denmark","startDate":"2018-01-10","conditions":"COPD, Respiratory Tract Infections, Pseudomonas Aeruginosa","enrollment":51},{"nctId":"NCT02437045","phase":"PHASE4","title":"Trial of Meropenem Versus Piperacillin-Tazobactam on Mortality and Clinial Response","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2015-04","conditions":"Bloodstream Infections","enrollment":100},{"nctId":"NCT03108690","phase":"PHASE4","title":"Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia","status":"WITHDRAWN","sponsor":"Sara Thønnings","startDate":"2017-10-01","conditions":"Bacteremia","enrollment":""},{"nctId":"NCT03985514","phase":"PHASE4","title":"Acute Appendicitis: Active Observation With and Without Antibiotics","status":"COMPLETED","sponsor":"Göteborg University","startDate":"2018-05-15","conditions":"Appendicitis","enrollment":126},{"nctId":"NCT04394182","phase":"NA","title":"Ultra Low Doses of Therapy With Radiation Applicated to COVID-19","status":"SUSPENDED","sponsor":"Fundacion GenesisCare","startDate":"2020-04-21","conditions":"Pneumonia, Viral, Cytokine Storm","enrollment":15},{"nctId":"NCT03922451","phase":"","title":"Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support","status":"TERMINATED","sponsor":"Boston Children's Hospital","startDate":"2019-08-27","conditions":"Drug Effect","enrollment":4},{"nctId":"NCT03485950","phase":"PHASE2","title":"Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-05-16","conditions":"Other Infectious Diseases","enrollment":100},{"nctId":"NCT04042077","phase":"PHASE3","title":"Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections","status":"TERMINATED","sponsor":"Menarini Group","startDate":"2019-09-25","conditions":"Surgical Site Infection","enrollment":268},{"nctId":"NCT01694069","phase":"PHASE4","title":"Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis","status":"TERMINATED","sponsor":"West Virginia University","startDate":"2012-09","conditions":"Cystic Fibrosis","enrollment":6},{"nctId":"NCT02991937","phase":"PHASE4","title":"Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2016-12","conditions":"Appendicitis","enrollment":39},{"nctId":"NCT02840136","phase":"NA","title":"LC-MS/MS Based Method Development for the Monitoring of Antibiotic Concentrations in Sputum of Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"University Ghent","startDate":"2016-02","conditions":"Cystic Fibrosis","enrollment":40},{"nctId":"NCT05060419","phase":"PHASE2","title":"Meropenem-FL058 Phase 2 Study in the Treatment of Complicated Urinary Tract Infections","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-10-08","conditions":"Complicated Urinary Tract Infection, Acute Pyelonephritis","enrollment":150},{"nctId":"NCT04132115","phase":"","title":"Optimized Antibiotic Therapy in Patients With Subarachnoid Haemorrhage (ES) and Cerebral Haemorrhage (EC)","status":"UNKNOWN","sponsor":"Azienda Sanitaria-Universitaria Integrata di Udine","startDate":"2019-10-01","conditions":"Therapeutic Drug Monitoring, Subarachnoid Hemorrhage, Intracerebral Hemorrhage","enrollment":104},{"nctId":"NCT04914039","phase":"","title":"Evaluation of CTA on the Assessment of Brain Death","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-02-01","conditions":"Brain Death","enrollment":63},{"nctId":"NCT04879030","phase":"PHASE2, PHASE3","title":"Combination Antibiotic Therapy Compared to Monotherapy in the Treatment of Acute COPD","status":"COMPLETED","sponsor":"Haiphong University of Medicine and Pharmacy","startDate":"2020-01-01","conditions":"COPD Exacerbation Acute","enrollment":170},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT04816968","phase":"PHASE1","title":"Antibiotics Continuous Infusion at Home","status":"UNKNOWN","sponsor":"Ospedale San Carlo Borromeo","startDate":"2021-09","conditions":"Severe Bacterial Infections","enrollment":50},{"nctId":"NCT04233996","phase":"PHASE4","title":"Efficacy of Extended Infusion of β-lactam Antibiotics for the Treatment of Febrile Neutropenia in Hematologic Patients","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2019-06-05","conditions":"Febrile Neutropenia","enrollment":150},{"nctId":"NCT03765645","phase":"NA","title":"Comparison of 9 Doses vs 3 Doses of Post Operative Antibiotics in Live Liver Donors","status":"COMPLETED","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2018-10-04","conditions":"Antibiotic Prophylaxis, Postoperative Infection","enrollment":126},{"nctId":"NCT02609646","phase":"","title":"AbioKin - Antibiotic Kinetics","status":"COMPLETED","sponsor":"Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva","startDate":"2016-01","conditions":"Critical Illness, Infection","enrollment":1500},{"nctId":"NCT03560232","phase":"PHASE4","title":"Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens","status":"TERMINATED","sponsor":"Mercy Health Ohio","startDate":"2018-07-09","conditions":"Open Fracture, Post-Op Wound Infection","enrollment":17},{"nctId":"NCT03140826","phase":"","title":"Amplification and Selection of Antimicrobial Resistance in the Intestine II","status":"COMPLETED","sponsor":"University Hospital Tuebingen","startDate":"2018-01-30","conditions":"Antibiotic Selection Pressure","enrollment":60},{"nctId":"NCT02795949","phase":"PHASE3","title":"Study on Reduced Antibiotic Treatment vs Broad Spectrum Betalactam in Patients With Bacteremia by Enterobacteriaceae","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2016-10","conditions":"Enterobacteriaceae Infections","enrollment":344},{"nctId":"NCT02611271","phase":"","title":"Elimination of Antibiotics During Renal Replacement Therapy and Cytosorb Adsorptive Therapy","status":"UNKNOWN","sponsor":"Heinrich-Heine University, Duesseldorf","startDate":"2017-12-01","conditions":"Critical Illness, Sepsis, Acute Kidney Injury","enrollment":30},{"nctId":"NCT03687255","phase":"PHASE3","title":"Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections","status":"COMPLETED","sponsor":"Allecra","startDate":"2018-09-24","conditions":"Urinary Tract Infections","enrollment":1043},{"nctId":"NCT03862079","phase":"PHASE2","title":"Fecal Transplant +/- Gut Decontamination in Preventing Acute Graft Versus Host Disease in Patients Given Broad-Spectrum Antibiotics","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-06-01","conditions":"Graft-versus-host Disease Prevention","enrollment":""},{"nctId":"NCT03036826","phase":"","title":"Computer-based Dosage Calculation for Antibiotics","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2019-06","conditions":"Acute Kidney Insufficiency, Anti-Infective Agent Toxicity","enrollment":""},{"nctId":"NCT03738683","phase":"","title":"Pharmacokinetics of Piperacillin and Tazobactam in Critically Ill Patients","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2019-02-01","conditions":"Bacterial Infections","enrollment":40},{"nctId":"NCT01994993","phase":"PHASE2, PHASE3","title":"Antibiotic Safety (SCAMP)","status":"COMPLETED","sponsor":"Michael Cohen-Wolkowiez","startDate":"2013-12","conditions":"Complicated Intra Abdominal Infections","enrollment":260},{"nctId":"NCT02753946","phase":"PHASE2, PHASE3","title":"Safety and Efficacy of ZTI-01 (IV Fosfomycin) vs Piperacillin/Tazobactam for Treatment cUTI/AP Infections","status":"COMPLETED","sponsor":"Nabriva Therapeutics AG","startDate":"2016-04","conditions":"Urinary Tract Infection Symptomatic, Acute Pyelonephritis, Urinary Tract Infection Complicated","enrollment":465},{"nctId":"NCT03006679","phase":"PHASE3","title":"A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia","status":"WITHDRAWN","sponsor":"Melinta Therapeutics, Inc.","startDate":"2018-08","conditions":"Hospital-Acquired Bacterial Pneumonia, Ventilator-Associated Bacterial Pneumonia, Hospital-Acquired Pneumonia","enrollment":""},{"nctId":"NCT01853982","phase":"PHASE3","title":"Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia","status":"TERMINATED","sponsor":"Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","startDate":"2013-06-14","conditions":"Ventilator-Associated Pneumonia (VAP)","enrollment":4},{"nctId":"NCT01923363","phase":"NA","title":"PK/PD of High Dose Pip/Tazo in Obese Patients","status":"COMPLETED","sponsor":"Loma Linda University","startDate":"2014-02-25","conditions":"Obesity","enrollment":29},{"nctId":"NCT00873327","phase":"PHASE1","title":"Pharmacokinetics and Safety of Piperacillin-tazobactam in Neonates","status":"COMPLETED","sponsor":"Phillip Brian Smith","startDate":"2009-10","conditions":"Sepsis","enrollment":32},{"nctId":"NCT01370616","phase":"PHASE3","title":"Ertapenem Sodium (MK-0826) Versus Piperacillin/Tazobactam Sodium for the Treatment of Diabetic Foot Infections in Chinese Adults (MK-0826-061)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-09-02","conditions":"Infection; Diabetic Foot","enrollment":565},{"nctId":"NCT00629135","phase":"PHASE3","title":"Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses","status":"COMPLETED","sponsor":"Hannover Medical School","startDate":"2005-11-15","conditions":"Abscess, Intra-Abdominal","enrollment":180},{"nctId":"NCT02168816","phase":"PHASE2","title":"Efficacy of Oral Antibiotic Therapy Compared to Intravenous Antibiotic Therapy for Osteomyelitis","status":"TERMINATED","sponsor":"Loyola University","startDate":"2014-03-19","conditions":"Osteomyelitis","enrollment":30},{"nctId":"NCT02166476","phase":"PHASE3","title":"Efficacy/Safety of Meropenem-Vaborbactam Compared to Piperacillin-Tazobactam in Adults With cUTI and AP","status":"COMPLETED","sponsor":"Melinta Therapeutics, Inc.","startDate":"2014-11-20","conditions":"Urinary Tract Infection Complicated, Acute Pyelonephritis","enrollment":550},{"nctId":"NCT03441529","phase":"PHASE1","title":"A Crossover Study to Assess the Effect of Intravenous Infusion of Piperacillin/Tazobactam on the Pharmacokinetics of Orally Administered Lumicitabine (JNJ-64041575) in Healthy Adult Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2018-02-09","conditions":"Healthy","enrollment":18},{"nctId":"NCT02466438","phase":"PHASE1","title":"Safety and Pharmacokinetics of Piperacillin-tazobactam Extended Infusion in Infants and Children (PIP-TAZO)","status":"UNKNOWN","sponsor":"St. Justine's Hospital","startDate":"2016-01","conditions":"Infection","enrollment":141},{"nctId":"NCT02619149","phase":"PHASE3","title":"Piperacllin Versus Placebo in Patients Undergoing Surgery for Acute Cholecystitis","status":"COMPLETED","sponsor":"Karolinska Institutet","startDate":"2009-03","conditions":"Cholecystitis, Acute","enrollment":100},{"nctId":"NCT03376529","phase":"PHASE1","title":"Phase 1 Study to Evaluate DDI, PK, Safety, Tolerability of SPR741","status":"COMPLETED","sponsor":"Spero Therapeutics","startDate":"2017-11-10","conditions":"Healthy Volunteers","enrollment":27},{"nctId":"NCT02176122","phase":"PHASE4","title":"RCT Meropenem vs Piperacillin-Tazobactam for Definitive Treatment of BSI's Due to Ceftriaxone Non-susceptible Escherichia Coli and Klebsiella Spp.","status":"TERMINATED","sponsor":"The University of Queensland","startDate":"2014-02","conditions":"Bloodstream Infections","enrollment":391},{"nctId":"NCT02730624","phase":"PHASE4","title":"Piperacillin/Tazobactam in Critically Ill Patients With Severe Sepsis and Septic Shock","status":"COMPLETED","sponsor":"Sutep Jaruratanasirikul","startDate":"2014-03","conditions":"Early Phase of Severe Sepsis and Septic Shock","enrollment":50},{"nctId":"NCT02732327","phase":"PHASE2","title":"Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer","status":"TERMINATED","sponsor":"Forest Laboratories","startDate":"2016-05-17","conditions":"Neoplasms, Febrile Neutropenia","enrollment":2},{"nctId":"NCT03120663","phase":"","title":"Target Attainment and Pharmacokinetics of Antimicrobials in Non-critically Ill Surgery Patients (TAPAS)","status":"UNKNOWN","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2016-11-30","conditions":"Surgery","enrollment":120},{"nctId":"NCT01290003","phase":"NA","title":"Role of Antibiotics in Preventing Infection in Babies Born Through Meconium Stained Liquor","status":"COMPLETED","sponsor":"Lady Hardinge Medical College","startDate":"2010-06","conditions":"Neonatal Sepsis","enrollment":250},{"nctId":"NCT00816790","phase":"PHASE4","title":"Standard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock","status":"TERMINATED","sponsor":"Fraser Health","startDate":"2009-01","conditions":"Septic Shock, Acute Renal Failure","enrollment":20},{"nctId":"NCT02463747","phase":"PHASE4","title":"Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia","status":"UNKNOWN","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2015-06","conditions":"Fever, Febrile Neutropenia","enrollment":110},{"nctId":"NCT01697059","phase":"NA","title":"Initial Antibiotics and Delayed Appendectomy for Acute Appendicitis","status":"COMPLETED","sponsor":"Rhode Island Hospital","startDate":"2012-09","conditions":"Acute Appendicitis","enrollment":73},{"nctId":"NCT00402727","phase":"PHASE3","title":"Comparison of Sequential IV/PO Moxifloxacin With IV Piperacillin/Tazobactam Followed by PO Amoxicillin/Clavulanic Acid in Patients With a Complicated Skin and Skin Structure Infection","status":"COMPLETED","sponsor":"Bayer","startDate":"2006-09","conditions":"Abscess, Wound Infection, Diabetic Foot","enrollment":813},{"nctId":"NCT02171338","phase":"PHASE4","title":"Procalcitonin as a Marker of Antibiotic Therapy in Patients With Lower Respiratory Tract Infections","status":"UNKNOWN","sponsor":"Holbaek Sygehus","startDate":"2013-10","conditions":"Pneumonia, Acute Exacerbation of Chronic Obstructive Airways Disease","enrollment":55},{"nctId":"NCT02191475","phase":"PHASE2, PHASE3","title":"Effect Study of Tigecycline to Treat Severe Sepsis and Septic Shock","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2014-05","conditions":"Abdominal Infection","enrollment":100},{"nctId":"NCT01714570","phase":"NA","title":"Piperacillin/Tazobactam for Empirical Therapy of Febrile Neutropenia","status":"COMPLETED","sponsor":"Chinese PLA General Hospital","startDate":"2012-11","conditions":"Febrile, Neutropenia, Hematopoietic Stem Cell Transplantation","enrollment":123},{"nctId":"NCT00044928","phase":"PHASE4","title":"Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2002-07","conditions":"Bacterial Infections","enrollment":262},{"nctId":"NCT00044746","phase":"PHASE4","title":"Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-10","conditions":"Diabetes Mellitus, Diabetic Foot","enrollment":314},{"nctId":"NCT00703144","phase":"PHASE4","title":"Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy","status":"COMPLETED","sponsor":"University Hospital, Toulouse","startDate":"2008-06","conditions":"Diffusive and Convective Clearance, Body Clearance, Piperacillin Tazocilline Concentrations (Cmin)","enrollment":10},{"nctId":"NCT00491426","phase":"","title":"Antimicrobial PK in Infants With Suspected or Confirmed Infection","status":"COMPLETED","sponsor":"Duke University","startDate":"2006-01","conditions":"Infection","enrollment":450},{"nctId":"NCT01714557","phase":"NA","title":"Prophylactic Piperacillin/Tazobactam in Hematopoietic Stem Cell Transplantation","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2012-09","conditions":"Neutropenia, Hematopoietic Stem Cell Transplantation","enrollment":150},{"nctId":"NCT00003805","phase":"PHASE3","title":"Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"1997-11","conditions":"Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection","enrollment":859},{"nctId":"NCT00488189","phase":"PHASE4","title":"Study Evaluation Tazocin Intervention","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2007-05","conditions":"Bacterial Infections","enrollment":134},{"nctId":"NCT00195533","phase":"","title":"Study Comparing Piperacillin-tazobactam Versus Piperacillin-tazobactam Plus Glycopeptide in Neutropenic Patients","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2001-07","conditions":"Hematological Malignancy, Leukemia, Myelodysplasia","enrollment":801},{"nctId":"NCT00195286","phase":"","title":"Study Evaluating Piperacillin/Tazobactam in Complicated Urinary Infections.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2004-06","conditions":"Urinary Infections","enrollment":180},{"nctId":"NCT00253955","phase":"PHASE3","title":"Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia","status":"COMPLETED","sponsor":"Sanofi","startDate":"2003-06","conditions":"Pneumonia","enrollment":460},{"nctId":"NCT00435305","phase":"","title":"Steady State Serum and Epithelial Lining Fluid (ELF) Antibiotics Concentrations Under Continous Infusion","status":"TERMINATED","sponsor":"University Hospital Tuebingen","startDate":"2006-11","conditions":"Pneumonia, Bacteremia","enrollment":40},{"nctId":"NCT00153634","phase":"NA","title":"Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)","status":"COMPLETED","sponsor":"Seattle Children's Hospital","startDate":"2004-03","conditions":"Cystic Fibrosis, Chronic Bronchitis","enrollment":75},{"nctId":"NCT00478855","phase":"PHASE4","title":"Tazocin Intervention Study","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2006-09","conditions":"Bacterial Infections","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tazocin","Zosyn","Piperacillin-Tazobactam"],"phase":"marketed","status":"active","brandName":"Piperacillin-tazobactam combination product","genericName":"Piperacillin-tazobactam combination product","companyName":"Gruppo Italiano per la Valutazione degli Interventi in Terapia Intensiva","companyId":"gruppo-italiano-per-la-valutazione-degli-interventi-in-terapia-intensiva","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Piperacillin-tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation. Used for Bacterial infections including intra-abdominal infections, gynecological infections, skin and soft tissue infections, and respiratory tract infections, Nosocomial pneumonia, Febrile neutropenia in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}